Search results for "CARDIOVASCOLARE"

showing 10 items of 338 documents

Anti-muscarinic drugs as preventive treatment of exercise-induced bronchoconstriction (EIB) in children and adults.

2020

Regular physical activity is strongly recommended to prevent chronic respiratory diseases, including asthma. On the other hand, vigorous physical training may trigger airway symptoms and bronchoconstriction. The transient airway narrowing occurring because of exercise is named exercise-induced bronchoconstriction (EIB). Despite management according to guidelines, a significant proportion of patients experiences uncontrolled EIB, which thus represents a relevant unmet medical need. In particular, although prevention and treatment of EIB are effectively based on the use of beta-2 bronchodilator drugs, high heterogeneity in individual responses has been reported. Furthermore, even though beta-…

Pulmonary and Respiratory MedicineAdultMalemedicine.medical_specialtyAdolescentmedicine.drug_classBronchoconstrictionMuscarinic Antagonists03 medical and health sciencesYoung Adult0302 clinical medicineBronchodilatorAdministration InhalationRespiratory HypersensitivityMedicineAdrenergic DrugsHumans030212 general & internal medicineIntensive care medicineAdverse effectChildAsthmabusiness.industrymedicine.diseaseResponse VariabilityExercise-induced bronchoconstrictionBronchodilator AgentsAnti-muscarinic030228 respiratory systemDelayed-Action PreparationsSettore MED/11 - MALATTIE DELL'APPARATO CARDIOVASCOLAREAnti muscarinicSystematic reviewBronchoconstrictionFemalemedicine.symptomAirwaybusinesshuman activitiesPhysical Conditioning HumanRespiratory medicine
researchProduct

Recommendations for the management of patients with obstructive sleep apnoea and hypertension.

2013

This article is aimed at addressing the current state-of-the-art in epidemiology, pathophysiology, diagnostic procedures and treatment options for appropriate management of obstructive sleep apnoea (OSA) in cardiovascular (in particular hypertensive) patients, as well as for the management of cardiovascular diseases (in particular arterial hypertension) in OSA patients. The present document is the result of work performed by a panel of experts participating in the European Union COST (Cooperation in Scientific and Technological research) Action B26 on OSA, with the endorsement of the European Respiratory Society and the European Society of Hypertension. In particular, these recommendations …

Pulmonary and Respiratory MedicineAdultMalemedicine.medical_specialtySleep apnoea COSTMEDLINEArterial hypertension continuous positive airway pressure treatment guidelines hypertension treatment obstructive sleep apnoeaCardiologyMyocardial IschemiaBlood PressureSettore MED/10 - Malattie Dell'Apparato Respiratoriota3111Renin-Angiotensin SystemRisk FactorsEpidemiologymedicinemedia_common.cataloged_instanceHumansIn patientObesityEuropean unionIntensive care medicineStrokeLife StyleSocieties Medicalmedia_commonAgedta3126InflammationSleep Apnea Obstructivebusiness.industryRespirationSleep apneaMED/11 - MALATTIE DELL'APPARATO CARDIOVASCOLAREMiddle Agedmedicine.diseaseObesityEuropeStrokeBlood pressureHypertensionFemaleEndothelium VascularbusinessThe European respiratory journal
researchProduct

Treatment of heart failure with preserved ejection fraction.

2018

Heart failure, in its diverse forms based on the value of the ejection fraction, is associated to high mortality and the frequent need for hospitalization, with a consequent heavy burden on healthcare resources. For an appropriate treatment of heart failure with preserved ejection fraction (HFpEF), there are no specific drugs effective for this condition. Those indicated in HF with reduced EF (HFrEF) are of more benefit in that form of HF, according to the guidelines of the European Society of Cardiology of 2016: ACE-inhibitors, beta-blockers, anti-aldosterones are all indicated with a class of recommendation/level of evidence IA; therapy with loop diuretics is indicated in the case of clin…

Pulmonary and Respiratory Medicinemedicine.medical_specialtyEjection fractionSettore MED/09 - Medicina Internalcsh:Medicineheart failuretherapeutic strategies.Hospitalization rateInternal medicineMedicineAerobic exerciseguidelinesEjection fraction; comorbidity; guidelines; heart failure; therapeutic strategies.Ejection fractionbusiness.industryHigh mortalitylcsh:REvidence-based medicinemedicine.diseaseSettore MED/11 - Malattie Dell'Apparato CardiovascolarecomorbidityHeart failureCardiologyCardiology and Cardiovascular MedicineHeart failure with preserved ejection fractionbusinessguidelineMonaldi archives for chest disease = Archivio Monaldi per le malattie del torace
researchProduct

INDICATORI DI RISCHIO CARDIOVASCOLARE E METABOLICO IN POPOLAZIONE GENERALE ADULTA SICILIANA

2008

RISCHIO CARDIOVASCOLARE
researchProduct

IL RISCHIO CARDIOVASCOLARE GLOBALE NELLA SINDROME METABOLICA DEL BAMBINO

2008

RISCHIO CARDIOVASCOLARE SINDROME METABOLICA
researchProduct

Ambulatory Blood Pressure Values in the Ongoing Telmisartan Alone and in Combination with Ramipril Global Endpoint Trial (ONTARGET)

2012

In the Ongoing Telmisartan Alone and in Combination with Ramipril Global Endpoint Trial, telmisartan (T; 80 mg daily) and ramipril (R; 10 mg daily) caused similar clinic blood pressure (BP) reductions, with a similar incidence of cardiovascular and renal events. The R+T combination lowered clinic BP somewhat more with no further cardiovascular or renal protection. The aim of this substudy was to see whether these clinic BP changes reflected the changes of 24-hour BP, a BP with a better prognostic value. In 422 patients in whom 24-hour BP monitoring was performed either before or after 6 to 24 months of treatment, demographic and clinical characteristics were similar in the 3 treated groups.…

RamiprilMalemedicine.medical_specialtyAmbulatory blood pressureDiastoleAngiotensin-Converting Enzyme InhibitorsBlood PressureBenzoateslaw.inventionRandomized controlled trialRamiprillawInternal medicineInternal MedicinemedicineHumansLongitudinal StudiesTelmisartanAntihypertensive AgentsAgedbusiness.industryambulatory blood pressure antihypertensive treatment high cardiovascular risk angiotensin-converting enzyme inhibitors angiotensin receptor blockersMED/11 - MALATTIE DELL'APPARATO CARDIOVASCOLAREBlood Pressure Monitoring AmbulatoryMiddle AgedEndocrinologyBlood pressureTreatment OutcomeTarget drugAmbulatoryHypertensionCardiologyBenzimidazolesDrug Therapy CombinationFemaleTelmisartanbusinessmedicine.drug
researchProduct

Peripheral artery disease: potential role of ACE-inhibitor therapy

2008

Giuseppe Coppola, Giuseppe Romano, Egle Corrado, Rosa Maria Grisanti, Salvatore NovoDepartment of Internal Medicine, Cardiovascular and Nephro-Urological Diseases, Chair of Cardiovascular Disease, University of Palermo, Palermo, ItalyAbstract: Subjects with peripheral arterial disease (PAD) of the lower limbs are at high risk for cardiovascular and cerebrovascular events and the prevalence of coronary artery disease in such patients is elevated. Recent studies have shown that regular use of cardiovascular medications, such as therapeutic and preventive agents for PAD patients, seems to be promising in reducing long-term mortality and morbidity. The angiotensin-converting-enzyme (ACE) system…

Ramiprillcsh:Diseases of the circulatory (Cardiovascular) systemmedicine.medical_specialtyPathologyACE inhibitorsEndocrinology Diabetes and MetabolismBradykininAngiotensin-Converting Enzyme InhibitorsReviewDiseaseendothelial dysfunctionCoronary artery diseasechemistry.chemical_compoundperipheral arterial diseaseInternal medicineHumansMedicinePharmacology (medical)Endothelial dysfunctionCell ProliferationSubclinical infectionPeripheral Vascular Diseasesbusiness.industryFibrinolysisPublic Health Environmental and Occupational HealthCardiovascular AgentsPeripheral artery disease ACE-inhibitorintermittent claudicationHematologyGeneral Medicinemedicine.diseaseSettore MED/11 - Malattie Dell'Apparato Cardiovascolareperipheral arterial disease.Oxidative StressTreatment OutcomeLower ExtremitychemistryCardiovascular Diseaseslcsh:RC666-701ACE-inhibitorsACE inhibitorCardiovascular agentCardiologyEndothelium VascularatherosclerosisCardiology and Cardiovascular Medicinebusinessmedicine.drugVascular Health and Risk Management
researchProduct

Alpha1-antitrypsin heterozygosity plays a positive role in attainment of longevity.

2007

Genes involved in cardiovascular diseases (CVD) play an opposite role in human longevity. The alpha1-antitrypsin (AAT) is a serine-protease inhibitor required for the prevention of proteolytic tissue damage, by neutrophil elastase. The role of AAT in CVD has not been definitively assessed and its effect on longevity has not yet fully been studied. To clarify these points, we have studied the distribution of AAT allele variants in 3 cohorts: 127 young patients affected by acute myocardial infarction (AMI), 255 young controls and 143 centenarians from Sicily. The Z allele frequency was most frequent in centenarians (13.3%), intermediate in healthy young controls (3.1%) and less frequent in AM…

SenescenceAdultMalemedicine.medical_specialtyAgingHeterozygotemedia_common.quotation_subjectPopulationLongevityMyocardial InfarctionBiologyGastroenterologyRisk AssessmentLoss of heterozygosityCohort StudiesGene FrequencyRisk FactorsAAT Serine-protease inhibitor AMI Longevity CentenariansInternal medicineGenotypemedicineHumansGenetic Predisposition to Diseasecardiovascular diseasesAlleleRisk factoreducationAllele frequencySicilymedia_commonSettore MED/04 - Patologia GeneraleGeneticsAged 80 and overeducation.field_of_studyLongevityMiddle AgedSettore MED/11 - Malattie Dell'Apparato CardiovascolareLogistic ModelsCase-Control Studiesalpha 1-AntitrypsinFemaleGeriatrics and GerontologyGerontologyBiogerontology
researchProduct

Documento di consenso intersocietario ANMCO/ISS/AMD/ANCE/ARCA/FADOI/ GICR-IACPR/SICI-GISE/SIBioC/SIC/SICOA/ SID/SIF/SIMEU/SIMG/SIMI/SISA Colesterolo …

2016

Atherosclerotic cardiovascular disease still represents the leading cause of death in western countries. A wealth of scientific evidence demonstrates that increased blood cholesterol levels have a major impact on the outbreak and progression of atherosclerotic plaques. Moreover, several cholesterol-lowering pharmacological agents, including statins and ezetimibe, have proven effective in improving clinical outcomes. This document is focused on the clinical management of hypercholesterolemia and has been conceived by 16 Italian medical associations with the support of the Italian National Institute of Health. The authors have considered with particular attention the role of hypercholesterole…

Settore BIO/12 - Biochimica Clinica E Biologia Molecolare ClinicaSettore MED/09 - Medicina InternaItalyCardiovascular DiseaseRisk FactorAnticholesteremic AgentHypercholesterolemiaSettore BIO/14 - FarmacologiaConsensuCardiology and Cardiovascular MedicineSettore MED/11 - Malattie Dell'Apparato CardiovascolareHuman
researchProduct

RUOLO DELL’ECOCOLOR DOPPLER TISSUTALE NELLA VALUTAZIONE DELLA CARDIOTOSSICITÀ DA CHEMIOTERAPICI

2010

Settore MED/06 - Oncologia MedicaSettore BIO/14 - FarmacologiaECOCOLOR DOPPLER TISSUTALE CARDIOTOSSICITÀ CHEMIOTERAPICISettore MED/11 - Malattie Dell'Apparato Cardiovascolare
researchProduct